Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C]-Ibrexafungerp in Healthy Males
NCT04307082Phase 1Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Dec 2019
- Primary completion
- May 2020
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrexafungerp in fungal infection, sponsored by SCYNEXIS, Inc. Primary endpoint: Mass balance at Day 20. Started Dec 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT04307082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04307082.